Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 3137Neoplasms 2472Carcinoma, Non-Small-Cell Lung 1886Prostatic Neoplasms 1635Colorectal Neoplasms 1435Lung Neoplasms 1308Multiple Myeloma 939Neoplasm Metastasis 928Leukemia, Myeloid, Acute 884Pancreatic Neoplasms 856Ovarian Neoplasms 810Melanoma 791Carcinoma, Hepatocellular 742Stomach Neoplasms 648Brain Neoplasms 641Recurrence 640Squamous Cell Carcinoma of Head and Neck 639Head and Neck Neoplasms 612Glioblastoma 573Lymphoma 550Uterine Cervical Neoplasms 545Triple Negative Breast Neoplasms 513Precursor Cell Lymphoblastic Leukemia-Lymphoma 509Carcinoma, Renal Cell 504Hematologic Neoplasms 466Endometrial Neoplasms 466Urinary Bladder Neoplasms 462Colonic Neoplasms 446Lymphoma, Non-Hodgkin 439Sarcoma 436

Interventions

Platinum 1Mitotane 1Etoposide 1Ethane 1Dichlorodiphenyldichloroethane 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ENSAT Stage I Adrenal Cortex Carcinoma × 1 year × Clear all
NCT03583710 2026-04-07

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

M.D. Anderson Cancer Center

Phase 3 Recruiting
240 enrolled

ENSAT Stage I Adrenal Cortex Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡